Next Article in Journal
Epigenetics, Nervous System Tumors, and Cancer Stem Cells
Next Article in Special Issue
Targeted Radionuclide Therapy
Previous Article in Journal
Evaluation of Changes in Tumor Shadows and Microcalcifications on Mammography Following KORTUC II, a New Radiosensitization Treatment without any Surgical Procedure for Elderly Patients with Stage I and II Breast Cancer
Previous Article in Special Issue
TRAF4, at the Crossroad between Morphogenesis and Cancer
Open AccessReview

An Evidence-Based Approach to the Use of Predictive Biomarkers in the Treatment of Non- Small Cell Lung Cancer (NSCLC)

by Cindy Quinton 1 and Peter M. Ellis 1,2,*
1
Juravinski Cancer Centre, 699 Concession, St Hamilton, Hamilton, ON L8V 5C2, Canada
2
Department of Oncology, McMaster University Hamilton, ON L8S 4L8, Canada
*
Author to whom correspondence should be addressed.
Cancers 2011, 3(3), 3506-3524; https://doi.org/10.3390/cancers3033506
Received: 9 August 2011 / Revised: 30 August 2011 / Accepted: 5 September 2011 / Published: 13 September 2011
(This article belongs to the Special Issue Cancer Diagnosis and Targeted Therapy)
Recent advances in the treatment of non-small cell lung cancer (NSCLC) have led to improvements in patient survival and quality of life. It is unclear whether molecular abnormalities associated with NSCLC cell survival, growth and proliferation are useful in predicting treatment benefit. We conducted a systematic review to establish which biomarkers contribute meaningfully to the management of NSCLC. A team of researchers searched PubMed and conference proceedings (ASCO, ESMO, IASLC, USCAP) using MESH terms for NSCLC and randomized trials (RCT), plus keywords for variables of interest. Evidence from multiple RCTs confirmed that histologic subtype is prognostic for survival and predictive of treatment efficacy and/or toxicity in NSCLC. Likewise, activating mutations of the epidermal growth factor receptor (EGFR) are associated with benefit from EGFR tyrosine kinase inhibitors in patients with advanced non-squamous NSCLC and should be assessed routinely. No biomarkers to date reliably predict response to anti-Vascular Endothelial Growth Factor (VEGF) therapies. There are inconsistent data on the role of ERCC1, BRCA, Beta tubulin III, RRM1, K-RAS, or TP-53 in treatment decisions. These tests should not be routinely used in selecting treatment at this time, whereas EML4/ALK translocations predict responses to specific targeted agents, the optimal assessment of this molecular abnormality has yet to be established. Personalized care of patients with NSCLC based on biomarkers is increasingly important to both clinical practice and research. View Full-Text
Keywords: Non-small-cell lung cancer; targeted therapy; epidermal growth factor receptor; tyrosine kinase inhibitor; molecular marker; biomarker Non-small-cell lung cancer; targeted therapy; epidermal growth factor receptor; tyrosine kinase inhibitor; molecular marker; biomarker
MDPI and ACS Style

Quinton, C.; Ellis, P.M. An Evidence-Based Approach to the Use of Predictive Biomarkers in the Treatment of Non- Small Cell Lung Cancer (NSCLC). Cancers 2011, 3, 3506-3524.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Search more from Scilit
 
Search
Back to TopTop